An excipient database now in existence should help manufacturers leverage existing data to assess the toxic risk posed by elemental impurities under the International Council on Harmonization Q3D guideline, said Mark Schweitzer of Novartis.
The database should be able to help the industry quantify some of the unknown risks in assessing the toxicity of elemental impurities for new and existing drug products. There are...